Adding Velcade Increased Overall Survival By 13.3 Months at Five-Year Analysis
Perifosine Increases PFS In Phase II Study
Researchers Identify Nine Cancer Genes-Five Linked to CLL For The First Time
Carfilzomib Demonstrates Clinical Benefit Rate of 64%
Single-Letter Mutation Found Responsible For Waldenstrom’s
New Methods Uncover 1,800 RNAs Linked To Breast Cancer
Gene Expression Analyses Can Guide MDS Treatments
Analysis Reveals Patient Subset With Lower PFS in Phase III Trial
Interim Results Show Vaccine Lowers Breast Cancer Recurrence
CTCs Do Not Affect Survival, But Could Signal Metastases
Childhood Cancer Survivors Do Not Have an Increased Risk Of Passing On Birth Defects
Trials Approved by NCI CTEP For the Month of December
FDA Grants Orphan Designation To Photofrin for Mesothelioma
Trending Stories
- Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
- Lawsuits brought against Tempus AI raise more questions than answers about DNA privacy in the AI era
- Vinay Prasad, oncologist and Twitter star, locked in debate over precision medicine
- GRAIL presses on with Galleri test despite missed primary endpoint in pivotal study
Where GRAIL sees signals of benefit in the subgroups, screening experts see signs of overdiagnosis - Kim Rathmell named OSUCCC director, Pollock becomes director emeritus in planned leadership transition
- GRAIL’s Megan Hall: “I think we can be confident that there is clinical benefit to implementing this technology. And I think that’s really hard to argue with.”
Mainstream epidemiologists beg to differ
